Home // LCSB // News & E... // Clinical research on Innovative Healthcare: Adaptive Platform Trials: The Clinical Trial of the Future

Clinical research on Innovative Healthcare: Adaptive Platform Trials: The Clinical Trial of the Future

twitter linkedin facebook email this page
Add to calendar
Speaker: Dr Ariel Dora Stern
Event date: Tuesday, 06 December 2022 04:00 pm - 05:30 pm
Place: Centre Hospitalier du Luxembourg (CHL) Amphitheatre
4 Rue Nicolas Ernest Barblé
1210 Luxembourg

Adaptive Platform Trials: The Clinical Trial of the Future

This lecture will present an overview of Adaptive Platform Trails (APTs), including key definitions and design considerations. It will then present a brief case study of GBM AGILE, a large-scale, international APT for glioblastoma that is currently underway at dozens of clinical sites, with multiple interventional trial arms. While statistically rigorous and still considered the “gold standard” in clinical research, traditional RCTs are time-consuming, costly, and remain limited to testing just one new therapy at a time. APTs, by contrast, facilitate simultaneously studying multiple therapies for a given disease and promise several efficiency improvements. They also use Bayesian statistical techniques to allow more patients access to promising therapies. As such, they hold the potential to fundamentally change the clinical research process, making clinical trials for new therapies more efficient, more accessible to patients, and more ambitious in scope. Yet new considerations emerge in the financing, regulatory science, and management of APTs. These will be discussed broadly and in the case of GBM AGILE in particular.

About the speaker:

Dr. Ariel Dora Stern is the Poronui Associate Professor of Business Administration in the Technology and Operations Management Unit at Harvard Business School, where she teaches the course “Transforming Health Care Delivery.” Ariel's research focuses on technology management and innovation in health care. Her projects consider the regulation, strategy, and economics of health care, with a focus on understanding the drivers of new product development among firms and the determinants of how new medical technologies are adopted and used in practice. She is a faculty affiliate of Ariadne Labs, a joint center for health systems innovation at Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health and the Harvard-MIT Center for Regulatory Science. From 2020-2021 Ariel served as the Director for International Health Care Economics at the Health Innovation Hub, the independent think tank of the German Federal Ministry of Health and from 2021-2022, as a Visiting Scholar at the Digital Health Center of The Hasso Plattner Institute. She is a member of the Scientific Advisory Board of the German Society for Digital Medicine and advises health care start-ups.

 

Tuesday 6 December - 16:00-17:30, Hybrid Meeting
Centre Hospitalier du Luxembourg (CHL) - Amphitheater
& WebEx: https://tinyurl.com/innovhealth4
[access code: 273 442 59834
password: mZtbPXHf344 (69827943 from phones)]

For on-site and remote registration, please drop an email to: Bianca.dragomir@lih.lu

This lecture series is organised jointly by the Prof. Rejko Krüger and Prof. Jochen Klucken on behalf of the research groups Translational Neuroscience (LCSB), Transversal Translational Medicine (LIH), and Digital Medicine (LIH, LCSB).

Data: 2022-12-06_InnovativeHealthcare.pdf 329.96 kB